JP2025507830A - ループス腎炎の処置のためのイプタコパンの使用 - Google Patents

ループス腎炎の処置のためのイプタコパンの使用 Download PDF

Info

Publication number
JP2025507830A
JP2025507830A JP2024551929A JP2024551929A JP2025507830A JP 2025507830 A JP2025507830 A JP 2025507830A JP 2024551929 A JP2024551929 A JP 2024551929A JP 2024551929 A JP2024551929 A JP 2024551929A JP 2025507830 A JP2025507830 A JP 2025507830A
Authority
JP
Japan
Prior art keywords
iptacopan
subject
dose
patient
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024551929A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507830A5 (https=
Inventor
リニック，ジャニーナ
メイアー，マティアス
ウェブ，ニコラス
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2025507830A publication Critical patent/JP2025507830A/ja
Publication of JP2025507830A5 publication Critical patent/JP2025507830A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024551929A 2022-03-04 2023-03-03 ループス腎炎の処置のためのイプタコパンの使用 Pending JP2025507830A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316623P 2022-03-04 2022-03-04
US63/316,623 2022-03-04
PCT/IB2023/052010 WO2023166487A1 (en) 2022-03-04 2023-03-03 Use of iptacopan for the treatment of lupus nephritis

Publications (2)

Publication Number Publication Date
JP2025507830A true JP2025507830A (ja) 2025-03-21
JP2025507830A5 JP2025507830A5 (https=) 2026-02-04

Family

ID=85704041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024551929A Pending JP2025507830A (ja) 2022-03-04 2023-03-03 ループス腎炎の処置のためのイプタコパンの使用

Country Status (10)

Country Link
US (1) US20250195492A1 (https=)
EP (1) EP4486343A1 (https=)
JP (1) JP2025507830A (https=)
KR (1) KR20240155291A (https=)
CN (1) CN118785906A (https=)
AU (1) AU2023229221A1 (https=)
CA (1) CA3248808A1 (https=)
IL (1) IL314494A (https=)
MX (1) MX2024010644A (https=)
WO (1) WO2023166487A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119656165A (zh) * 2023-09-20 2025-03-21 上海美悦生物科技发展有限公司 杂环化合物在制备预防和/或治疗肾脏疾病的药物中的用途
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183512A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CN120208923A (zh) 2020-05-18 2025-06-27 诺华股份有限公司 Lnp023的结晶形式

Also Published As

Publication number Publication date
AU2023229221A1 (en) 2024-08-15
EP4486343A1 (en) 2025-01-08
IL314494A (en) 2024-09-01
WO2023166487A1 (en) 2023-09-07
CA3248808A1 (en) 2023-09-07
US20250195492A1 (en) 2025-06-19
KR20240155291A (ko) 2024-10-28
MX2024010644A (es) 2024-09-06
CN118785906A (zh) 2024-10-15

Similar Documents

Publication Publication Date Title
US20200368247A1 (en) Cenicriviroc for the treatment of fibrosis
Gold et al. Progress in the treatment of myasthenia gravis
US20200360347A1 (en) Cenicriviroc for the treatment of fibrosis
JP2017526713A (ja) 線維症を処置するためのセニクリビロック併用療法
JP2025507830A (ja) ループス腎炎の処置のためのイプタコパンの使用
EP3185881B1 (en) Methods, agents and compositions for treatment of inflammatory conditions
CN105228453A (zh) 用于治疗与炎症相关的疾病的去乙基羟氯喹
EP4355329A1 (en) Method of treating an autoimmune hematological disorder
KR20240004947A (ko) 비정형 용혈성 요독 증후군 치료용 입타코판
McCormack et al. Cyclosporin therapy in severe ulcerative colitis: is it worth the effort?
Baldini et al. From clinical trials to the bedside: how can we treat patients with rheumatoid arthritis and concurrent morbidities who are generally excluded from randomised controlled clinical trials
Meyrier Management of idiopathic nephrotic syndrome in adults: minimal change disease and focal segmental glomerulosclerosis
KR20250150635A (ko) 인자 b 억제제의 사용 방법
Appel et al. New diagnostic tests and new therapies for glomerular diseases
WO2025172910A1 (en) Factor b inhibitors for treatment of anca-associated vasculitis
Ingold et al. Successful targeting of the alternative complement cascade with iptacopan for the treatment of IgA nephropathy: a case report
Ahamadi et al. SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTING WITH GUILLAIN–BARRE SYNDROME: A CASE REPORT
Wang et al. Minimal Change Disease
Veldandi et al. An adaptive, dose-exploration, Phase 2 trial evaluating efficacy and safety of iptacopan in combination with standard-of-care with and without oral corticosteroids in active lupus nephritis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260126